Full-Time
Performance Management Analyst
Medical Economics, Provider Economics
Posted on 10/31/2025
agilon health
501-1,000 employees
Value-based primary care platform for seniors
Compensation Overview
$87k - $106.6k/yr
Columbus, OH, USA
Remote
 Data & Analytics (4) |
|---|
| , , , |
- Bachelor’s degree in Mathematics, Finance, Actuarial Science, Statistics, or other quantitative/data science area of focus, Master’s degree preferred.
- Minimum of three years experience working for a health plan or medical group in a Medical Economics &/or Provider Economics capacity.
- Requires excellent communication, analytical, facilitation and problem-solving skills .
- Quantitative Reasoning and practical thinking methodology, Data Process Modeling. Strong attention to detail.
- Computer proficiency in Microsoft Office (Word, Excel, Outlook); Access &/or SQL strongly preferred.
- Strong interest in working with large / complex / segmented data sets and extract, analyze, and interpret financial / operational / clinical data to address business questions across organization.
- Strong interest in learning healthcare industry concepts.
- Strong desire to join & grow with a high performing, result-driven analytics teams.
- Provide key stakeholders with critical business insights and performance metrics through the use of complex data analysis methods and modeling
- Effectively translate complex business needs into actionable data modeling exercises.
- Communicate to key stakeholders the results and recommended action items uncovered during analytical exercises
- Function in a highly matrixed, fast-paced and team-based environment.
- Act as a liaison between Analytics and operational departments within the market.
- Support Information Services, Analytics and agilon leadership to drive initiatives with provider partners, payers and the management service organization (MSO) that partners with the RBE.
- Support the operational infrastructure through timely reporting with ongoing focus on organizational effectiveness, continued integration with agilon health and enhancing the ability to manage the cost of care.
- Perform analysis on an ad hoc basis as required to support the strategic and operational needs of the market leadership team.
- Participate in business process improvement efforts to collect and analyze metrics and continually improve processes by the organization and client groups.
- In collaboration with the Data Solutions team, develop and catalog standard management reports and corresponding business rules.
- Learn to use tools and technologies employed across agilon health .
- Drive high quality results by focusing on supporting the organizational needs.
- Leverage and embrace technology to drive process improvement, operational efficiency, and improved outcomes.
- Work collaboratively with colleagues to continue to define and support the agilon culture within the market and across the company.
agilon health builds a Medicare-focused value-based primary care network. It partners with independent primary care physicians to deliver senior care through a unified operating platform that connects payors, physicians, and patients. The platform combines people, processes, and technology to help physician partners close gaps in care, integrate with payors, and grow their practices, while enabling predictable margins and improved patient experience. Unlike models that push physicians to join large owned practices, agilon health keeps clinicians independent and supports them with coordinated care delivery and financial certainty. The company’s goal is to improve health outcomes for seniors by expanding access to quality primary care, aligning incentives across physicians, payors, and patients, and driving value-based care at scale.
Company Size
501-1,000
Company Stage
IPO
Headquarters
Long Beach, California
Founded
2016
Simplify's Take
What believers are saying
- Q1 2026 beat raises full-year revenue guidance to $5.7 billion.
- Generative AI and clinical pathways deployed in 90% markets boost margins.
- Tim O'Rourke's Humana experience drives value-based care expansion since May 7.
What critics are saying
- Kaskela and Bragar lawsuits over false medical cost guidance dilute shares.
- 7.5% medical cost growth in 2026 erodes margins per Barclays conference.
- Medicare Advantage membership declines undermine $5.7B revenue target.
What makes agilon health unique
- Total Care Model empowers independent physicians with platform for Medicare global risk.
- Unified platform integrates payer data, AI risk stratification across 85% of members.
- Partnerships with 2,200 physicians in 30 communities focus on senior total care.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Remote Work Options
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 0%2 year growth
↑ 0%AGILON HEALTH STOCKHOLDER ALERT: Kaskela Law firm announces Stockholder investigation of Agilon Health, inc.and encourages long-term AGL stockholders to contact the firm. March 31, 2026 08:15 ET | Source: Kaskela Law PHILADELPHIA, March 31, 2026 (GLOBE NEWSWIRE) - Stockholder rights firm Kaskela Law announces that it is investigating Agilon Health, Inc. (NYSE: AGL) ("Agilon") on behalf of the company's long-term investors. "Our firm is investigating whether the members of Agilon's board of directors violated the securities laws or breached their fiduciary duties" Recently a securities fraud complaint was filed against Agilon on behalf of certain investors who purchased shares of the company's stock between April 15, 2021 and February 27, 2024. According to the complaint, during that time period Agilon and several of the company's senior executive officers made a series of materially false and misleading statements to investors about Agilon's medical costs. As further detailed in the complaint, as the true information about the company's higher medical costs was disclosed as Agilon reported lower than expected financial results and expectations for future revenue, shares of the company's stock significantly declined in value, harming the company's long-term investors. Specifically, Agilon's stock price declined approximately 85% in value during the relevant period from over $44.00 per share to less than $6.50 per share, a decline of over $38.00 per share. "The allegations of misconduct involving the company's senior executives are deeply concerning. Our firm is investigating whether the members of Agilon's board of directors violated the securities laws or breached their fiduciary duties in connection with this alleged wrongdoing," said attorney D. Seamus Kaskela, who is leading the firm's investigation. Current Agilon shareholders who purchased or acquired their shares prior to May 1, 2023 are encouraged to contact Kaskela Law LLC (D. Seamus Kaskela, Esq. or Adrienne Bell, Esq.) at (484) 229 - 0750, or by email at [email protected] or [email protected], to discuss their no-cost legal rights and options with respect to this matter. You can also click on the following link (or copy and paste it into your browser) to learn more about this investigation: ABOUT KASKELA LAW: Kaskela Law exclusively represents investors in securities fraud, corporate governance, and merger & acquisition litigation on a contingent basis. For additional information about the firm, including the firm's recent monetary recoveries for investors in mergers & acquisition litigation, please visit our website (www.kaskelalaw.com) or contact us today at (888) 715 - 1740. KASKELA LAW LLC D. Seamus Kaskela, Esquire Adrienne Bell, Esquire 18 Campus Boulevard, Suite 100 Newtown Square, PA 19073 (484) 229 - 0750 www.kaskelalaw.com This communication may constitute attorney advertising in certain jurisdictions.
Why agilon health (AGL) stock is down today. Kayode omotosho /. March 12, 2026 What happened? Shares of healthcare services company Agilon Health (NYSE:AGL) fell 7.6% in the afternoon session after the stock's weakness continued as the company provided its financial outlook at the Barclays 28th Annual Global Healthcare Conference, which included a forecast for rising costs in 2026. During the presentation, agilon health stated that its cost trends were forecasted to grow 7.5% in 2026, with a net growth of 7%. This projection likely raised concerns among investors about the company's future profitability. While the company also shared some positive long-term goals, such as aiming for free cash flow break-even by 2027 and expecting a $125 million benefit from contracting improvements, the more immediate news of rising costs appeared to weigh on investor sentiment. The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy agilon health? Access our full analysis report here, it's free. What is the market telling us. agilon health's shares are extremely volatile and have had 82 moves greater than 5% over the last year. In that context, today's move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business. The previous big move we wrote about was 6 days ago when the stock dropped 13.5% on the news that a disappointing February jobs report revealed an unexpected contraction in employment, with significant job losses in the healthcare sector. The U.S. economy lost 92,000 nonfarm payroll jobs, a sharp reversal from the 50,000 gain that economists had anticipated. The healthcare industry, typically a source of job growth, shed 28,000 positions. This was a stark contrast to its strong gains in the previous month. The discouraging data raised investor concerns about a potential economic slowdown, which could lead to reduced healthcare spending and demand for services. The Labor Department noted that the drop in healthcare hiring was partly due to recent strike activity. agilon health is down 11.8% since the beginning of the year, and at $0.59 per share, it is trading 89.5% below its 52-week high of $5.68 from April 2025. Investors who bought $1,000 worth of agilon health's shares at the IPO in April 2021 would now be looking at an investment worth $19.16. ALSO WORTH WATCHING: Nvidia's Quiet Partner. Nvidia's chips cost a hundred grand. The connectors that make them work cost even more. One company makes them all. Every AI server needs specialized infrastructure the chip companies don't make. High-speed cables. Power connectors. Thermal sensors. This 90-year-old company built a monopoly on it. The AI boom just started. This stock is still flying under the radar. Claim The Stock Ticker Here for FREE.
Shares of Agilon Health fell 2% following a stronger-than-expected US Producer Price Index report for January. The PPI rose 0.5%, surpassing economists' forecasts of 0.3%, indicating persistent inflationary pressures. The data sparked concerns that the Federal Reserve might delay anticipated interest rate cuts. Higher interest rates for longer periods can negatively affect corporate valuations and borrowing costs, triggering a broad market downturn across sectors including healthcare. The decline follows yesterday's 18% gain after Agilon reported mixed fourth-quarter results, with revenue beating expectations but earnings missing forecasts. The stock is down 12% year-to-date and trading 89.6% below its 52-week high of $5.68 from April 2025.
Agilon Health shares jumped 18% after the healthcare services company reported fourth-quarter 2025 results that pleased investors despite mixed signals. Revenue reached $1.57 billion, up 3.1% year-over-year and beating Wall Street expectations. The company also provided optimistic EBITDA guidance for the upcoming quarter that surpassed analyst forecasts. However, Agilon reported a GAAP loss of $0.46 per share, missing consensus estimates. Its revenue guidance for the first quarter of 2026 came in at $1.37 billion, falling short of analysts' projections. Investors appeared to focus on the strong revenue beat and encouraging profitability forecast. The stock is down 11.4% year-to-date and trading 89.5% below its 52-week high of $5.68.
Agilon Health, a healthcare services company, reported fourth-quarter revenue of $1.57 billion, beating analyst estimates of $1.46 billion and representing 3.1% year-on-year growth. However, the company posted a GAAP loss of $0.46 per share, missing expectations by 69.1%. The company's first-quarter revenue guidance of $1.37 billion disappointed, coming in 12.6% below analyst estimates of $1.57 billion. Adjusted EBITDA was negative $141.9 million, down 69% year on year, whilst operating margin fell to negative 12.3% from negative 7.1% in the prior year. Agilon Health's customer base grew to 511,000, up from 503,000 in the previous quarter. The company, which helps primary care physicians transition to value-based care models for Medicare patients, has a market capitalisation of $163.5 million.